Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Fruno who wrote (12809)	4/30/2014 2:57:04 PM
From: Howard Williams	2 Recommendations Recommended By Jack Russell Mark Buczynski Read Replies (1) \| Respond to of 13111

That's a good article Fruno. Agarwala has a number of good things to say about PV-10. I think a good indicator that he may see a brighter future for PV-10 than conveyed by that article is what's coming next week. Next Wednesday is the opening day of the 10th European Association of Dermato Oncolgy congress in Vilnius, Lithuania. http://www.eado2014.com/ "The European Association of Dermato-Oncology (EADO) congress has become a stimulating and well-established annual event attracting hundreds of participants from the entire world. EADO meeting is the place, where clinicians and researchers can share the most new data and the best review, as well as practical information in the fields of melanoma and non-melanoma skin cancer." Checking the Scientific Program ..... http://www.eado2014.com/user/_files/30/EADO_2014.pdf .... you will find, in the opening session ...... "Intralesional PV-10", presented by Sanjiv S. Agarwala Not an overview of a spectrum of melanoma treatments ....... just PV-10. I sincerely doubt he'd journey to Vilnius to speak solely about PV-10 if he thought it was just one of many treatment options. Footnote: He's also running one of the three PV-10 liver cancer clinical trials.